JAMA oncology 2019-06-01
Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial.
Abstract
Importance
Consensus is lacking as to the optimal radiotherapy dose and fractionation schedule for treating bone metastases.
Objective
To assess the relative efficacy of high-dose, single-fraction stereotactic body radiotherapy (SBRT) vs standard multifraction radiotherapy (MFRT) for alleviation of pain in patients with mostly nonspine bone metastases.
Design, setting, and participants
This prospective, randomized, single-institution phase 2 noninferiority trial conducted at a tertiary cancer care center enrolled 160 patients with radiologically confirmed painful bone metastases from September 19, 2014, through June 19, 2018. Patients were randomly assigned in a 1:1 ratio to receive either single-fraction SBRT (12 Gy for ≥4-cm lesions or 16 Gy for <4-cm lesions) or MFRT to 30 Gy in 10 fractions.
Main outcomes and measures
The primary end point was pain response, defined by international consensus criteria as a combination of pain score and analgesic use (daily morphine-equivalent dose). Pain failure (ie, lack of response) was defined as worsening pain score (≥2 points on a 0-to-10 scale), an increase in morphine-equivalent opioid dose of 50% or more, reirradiation, or pathologic fracture. We hypothesized that SBRT was noninferior to MFRT.
Results
In this phase 2 noninferiority trial of 96 men and 64 women (mean [SD] age, 62.4 [10.4] years), 81 patients received SBRT and 79 received MFRT. Among evaluable patients who received treatment per protocol, the single-fraction group had more pain responders than the MFRT group (complete response + partial response) at 2 weeks (34 of 55 [62%] vs 19 of 52 [36%]) (P = .01), 3 months (31 of 43 [72%] vs 17 of 35 [49%]) (P = .03), and 9 months (17 of 22 [77%] vs 12 of 26 [46%]) (P = .03). No differences were found in treatment-related toxic effects or quality-of-life scores after SBRT vs MFRT; local control rates at 1 and 2 years were higher in patients receiving single-fraction SBRT.
Conclusions and relevance
Delivering high-dose, single-fraction SBRT seems to be an effective treatment option for patients with painful bone metastases. Among evaluable patients, SBRT had higher rates of pain response (complete response + partial response) than did MFRT and thus should be considered for patients expected to have relatively long survival.
Trial registration
ClinicalTrials.gov identifier: NCT02163226.
Related Questions
Would you offer 12-16 Gy in a single fraction for a symptomatic, non-vertebral bone metastasis?
Yes.We have randomized, prospective studies indicating that dose-escalation with 1-2 fractions improves control of pain over conventional RT doses - here and here. We also have a meta-analysis showing higher chance of complete response of pain with SBRT. In addition, the Canadian investigators showe...
Do you routinely offer spine SBRT for vertebral metastases regardless of overall patient disease burden or response?
I presume this will be controversial, but I tend to offer SBRT if feasible for palliation of pain from bone metastases. We have two positive studies (MDACC for non-spine, Canadian for spine) and one negative study. In addition, these are just 1-2 treatments. Billing becomes an issue, as I’ve continu...
How do you dose or sequence therapy to overcome radioresistance from oligometastatic disease from RCC?
RAPPORT (NCT02855203) [Siva et al., PMID 34953600] was a phase I/II trial which used a combination of RT and pembrolizumab. RT was given with SBRT (20 Gy/1# prescribed to the 80% isodose line) or conventional radiotherapy (30 Gy/10#) when the treatment volume was in close proximity to a dose-limitin...
How would you manage a treatment-naive patient who has painful vertebral lesions from ES-SCLC?
ES-SCLC is incurable. If they are in pain, treat their pain. Chemotherapy is palliative. TRT may extend life, but the average life expectancy with ES-SCLC is limited. Don't let patients in pain suffer when we have an effective way to treat them. I would consider very short courses - 1-2 fx SBRT (per...
Do you still recommend SBRT for oligometastatic and oligoprogressive breast cancer after the abstracts of the BR002 and CURB, respectively?
"Absence of evidence is not evidence of absence." The negative trials have put a damper on enthusiasm for these patients. This is interesting in light of past training and thinking where breast cancer patients with solitary or few metastases were thought to be emblematic of those that we could poten...
Do you ever consider local therapy to oligometastatic hormone-receptor positive breast cancer?
Surgery or radiation therapy in metastatic breast cancer patient is one of hot topics in care of the patients with stage IV disease, especially since the survival of oligometastatic breast cancer and widely spread metastatic breast cancer is vastly different. For instance, the 5 year survival of oli...